BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
Key Highlights
- ➤111 heavily pretreated MBC patients comprised the prospective pooled biomarker analysis
- ➤T2 CAML PD-L1 significantly associated with PFS (HR=2.73; p=0.0028) and OS (HR=2.27; p=0.0420)
- ➤T1 CAML PD-L1 significantly associated with PFS (HR=1.86; p=0.0276), not OS
- ➤Pretreatment tumor PD-L1 CPS of 10 or greater was not significantly associated with improved PFS or OS
- ➤BriaCell’s pivotal Phase 3 Bria-IMT combination study remains ongoing
Expert Statements
William V. Williams, President and CEO of BriaCell
“We are encouraged by these findings showing that dynamic changes in a circulating immune biomarker were associated with progression-free and overall survival in patients with metastatic breast cancer treated with immunotherapies”
William V. Williams, President and CEO of BriaCell
“These results support further study of CAML PD-L1 as a potential tool for understanding treatment response and identifying patients most likely to benefit from immunotherapy, including the Bria-IMT regimen.”
Giuseppe Del Priore, Chief Medical Officer of BriaCell
“These findings suggest that monitoring dynamic PD-L1 changes in circulating tumor-associated immune cells following initiation of immunotherapy may provide information regarding clinical benefit in patients with MBC and are consistent with findings reported in the Bria-IMT Phase 2 study.”
Giuseppe Del Priore, Chief Medical Officer of BriaCell
“Further studies are needed to validate CAML PD-L1 as a predictive biomarker.”
* Dynamic changes in PD-L1 expression on circulating cancer-associated macrophage-like cells (CAML) were significantly associated with progression-free survival and overall survival following immunotherapies including the BriaCell regimen * Findings from a prospective pooled analysis of 111 heavily pretreated metastatic breast cancer patients support further evaluation of circulating CAML PD-L1 as a potential biomarker of clinical benefit from immunotherapies * Pooled analysis includes patients from multiple studies, including BriaCell’s earlier Phase 1/2 Bria-IMT™ study PHILADELPHIA and VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with metastatic breast cancer (“MBC”) treated with immune based therapies including the BriaCell regimen at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place October 23-27, 2026 in Madrid, Spain. The data shown is pooled from several studies including BriaCell’s Phase 1/2 Bria-IMT study.
Get started
Create a free account to read the full story.